Werewolf Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

HOWL$1.010.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	WEREWOLF THERAPEUTICS, INC.
Date: March 27, 2026	By:	/s/ Daniel J. Hicklin
		Daniel J. Hicklin, Ph.D.
		President and Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Daniel J. Hicklin, Ph.D.
SIGNATURE	TITLE	DATE
/s/ Daniel J. Hicklin	President, Chief Executive Officer and Director (Principal Executive Officer)	March 27, 2026
/s/ Michael Urban	Vice President of Finance and Corporate Controller (Principal Financial and Accounting Officer)	March 27, 2026
Michael Urban
/s/ Luke Evnin	Chair of the Board of Directors	March 27, 2026
Luke Evnin, Ph.D.
/s/ Michael B. Atkins	Director	March 27, 2026
Michael B. Atkins, M.D.
/s/ Meeta Chatterjee	Director	March 27, 2026
Meeta Chatterjee, Ph.D.
/s/ Briggs W. Morrison	Director	March 27, 2026
Briggs W. Morrison, M.D.
/s/ Michael A. Sherman	Director	March 27, 2026
Michael A. Sherman, M.B.A.
/s/ Anil K. Singhal	Director	March 27, 2026
Anil K. Singhal

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.